Summary
Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K report on February 25, 2008, detailing the completion of two significant financing events on February 19, 2008. The company successfully offered $287.5 million in aggregate principal amount of 4.75% convertible senior subordinated notes due 2013, including the full exercise of the underwriters' over-allotment option. Concurrently, Vertex also completed an offering of 6,900,000 shares of common stock, again with the underwriters exercising their over-allotment option for an additional 900,000 shares. These offerings provide Vertex with substantial capital to support its ongoing operations and growth initiatives. The convertible notes carry a 4.75% annual interest rate, mature in February 2013, and are convertible into Vertex common stock at a conversion price of approximately $23.14 per share. The company retains the option to redeem these notes after February 15, 2010, under specified conditions, and holders have the right to require repurchase upon certain fundamental changes. The subordinated nature of the notes and the lack of restrictions on incurring additional senior debt are important considerations for investors.
Key Highlights
- 1Vertex Pharmaceuticals completed a $287.5 million offering of 4.75% convertible senior subordinated notes due 2013.
- 2The company also completed a concurrent offering of 6.9 million shares of common stock.
- 3Underwriters fully exercised their over-allotment options in both the note and stock offerings.
- 4The convertible notes mature on February 15, 2013, and bear interest at 4.75% per annum.
- 5Notes are convertible into Vertex common stock at a conversion price of approximately $23.14 per share.
- 6Vertex has the option to redeem the notes on or after February 15, 2010, under specified terms.
- 7The convertible notes are unsecured and subordinated to future senior debt.